Group 1 - The company is nearing the end of Phase I clinical trials for its innovative drug JX2201, which targets lipid reduction [1] - The company has submitted the application for the market approval of its generic drug, hydrochloride caliraheptine capsules, and it is progressing normally [1] - The company encourages stakeholders to pay attention to its regular reports for further updates on clinical indicators and future plans [1]